Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I-II study of convalescent plasma and Nanogam plus for SARS-CoV-2 neutralizing antibodies in B-cell depleted adults
NL-OMON22629Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of Nanogam Plus and convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Erasmus MC. Primary endpoints: Pharmacokinetics of virus neutralizing antibodies of convalescent plasma and Pharmacokinetics of virus neutralizing antibodies of Nanogam plus. Started Apr 2021; status: recruiting.
02
Drugs
Nanogam Plusconvalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON22629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22629.